View Older Stories View More Recent Stories
-
CDC Panel Votes Against Requiring Prescriptions For Covid Shots - Bloomberg
-
CDC Panel Votes To End Universal Recommendation For Covid Shots - Bloomberg
-
Kennedy To Change Childhood Vaccine Schedule In Sept: Monarez - Bloomberg
-
UBS Reiterates Buy Rating on Moderna (MRNA) as Drastic Change to COVID-19 Vaccine Access Appears Unlikely
-
Moderna COVID-19 vaccine shows 8-fold antibody increase against LP.8.1 variant
-
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans
-
Moderna reinforces that there are no new safety concerns for Spikevax vaccine
-
Moderna (MRNA) call put ratio 2.6 calls to 1 put, share price down 6.7%
-
Pfizer, Moderna, BioNTech trade lower amid report of vaccine link to child deaths
-
US officials plan to link 25 child deaths to covid shots - WaPo
-
RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
-
Rfk Jr. Moves To Add More Hand-picked Vaccine Advisory Members - Bloomberg
-
Moderna to present rare disease data at metabolism congress
-
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
-
White House Taps Top RFK Jr. Deputy As Acting CDC Director - Washington Post
-
CDC Director Monarez Is Being Ousted - WAPO
-
Moderna receives FDA approval for updated COVID-19 vaccines
-
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2
-
FDA Authorizes Covid Vaccines For Those At Higher Risk - Kennedy
-
Health Canada approves Moderna COVID-19 vaccine targeting LP.8.1 variant
-
Moderna to Present at Upcoming Conferences in September 2025
-
Bernstein on Moderna (MRNA): 'Still a Long Road to Profitability'
-
UBS Reiterates Buy Rating on Moderna (MRNA)
-
Moderna (MRNA) PT Lowered to $24 at BofA Securities
-
Moderna (MRNA) PT Lowered to $18 at Leerink Partners
-
Moderna (MRNA) PT Lowered to $25 at TD Cowen
-
Moderna (MRNA) Tops Q2 EPS by 85c; offers guidance
-
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
-
Moderna (MRNA) says UK Court of Appeal has upheld the validity of Moderna's EP'949 patent
-
UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
-
Moderna earnings preview Q2: set for weak qtr amid softer vaccine sales, regulatory headwinds
-
Moderna (MRNA) call put ratio 1 call to 1 put into quarter results
-
Moderna (MRNA) call put ratio 1.6 calls to 1 put into quarter results
-
Moderna receives European approval for updated COVID-19 vaccine
-
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
-
Moderna to present cancer therapy data at ESMO Congress in October
-
Moderna Announces Data to be Presented at ESMO Congress 2025
-
Moderna receives positive EMA Committee opinion for COVID-19 mRNA Vaccine targeting the SARS-CoV-2 Variant LP.8.1
-
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
-
U.S. large biotech stocks Q2 earnings preview
-
Moderna (MRNA) cancels plans to build Japan plant
-
Brookline on Moderna (MRNA): 'We estimate COVID-19 vaccines could have 2025 global sales of $2.4 billion'
-
Moderna (MRNA) Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease
-
Moderna (MRNA) call put ratio 8.8 calls to 1 put with a focus on short duration July 11 weekly calls as share price up 11.5%
-
William Blair Reiterates Market Perform Rating on Moderna (MRNA) 'Competition in the space and waning vaccine sentiment are negatively impacting the base business'
-
Moderna (MRNA) Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
-
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
-
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
-
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025
-
Kennedy Removing All Members Of CDC Panel Advising On Vaccines
